JNJ-49095397
JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].
Product Specifications
CAS Number
[1220626-82-3]
Product Name Alternative
RV568
UNSPSC
12352005
Target
P38 MAPK; Src
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jnj-49095397.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=NC=CC(COC2=C3C=CC=CC3=C(NC(NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5)=O)C=C2)=C1)COC
Molecular Formula
C34H36N6O4
Molecular Weight
592.69
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
P38α; p38γ
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human FXN shRNA (UAS) - Lentiviral human FXN shRNA (UAS, RFP) plasmid
GGTB2, CT (Beta-1,4-galactosyltransferase 1, Beta-1,4-GalTase 1, Beta4Gal-T1, b4Gal-T1, UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 1, UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1, Processed beta-1,4-galactosyltransferase 1, Lactose Synthase A Protein, N-acetyllactosamine Synthase, Nal Synthase, Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase, Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase, B4GalT1) (MaxLight 650) discontinued